Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4348

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-4348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Fluticasone Propionate and Salmeterol Inhalation Powder 500 mcg / 50 mcg in powder form, supplied as 60 blisters. The label notes storage instructions to keep dry and away from heat or sunlight, with a discard time of one month after opening. The product is repackaged by RemedyRepack Inc., Indiana, PA, and originally manufactured by Prasco Laboratories, Mason, OH. It includes warnings to keep out of reach of children and to store at controlled room temperatures.*

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure of the active ingredients fluticasone propionate and salmeterol, depicted as a molecular diagram showing the arrangement of atoms and bonds in the compound.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure diagram showing two molecular structures identified as the active ingredients in Fluticasone Propionate and Salmeterol DISKUS. The structures depict detailed arrangements of atoms and bonds typical for fluticasone propionate and salmeterol molecules used in respiratory powder inhalation therapy.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

A line graph depicting the percentage change in FEV1 over 12 weeks and at an endpoint for four groups: fluticasone propionate/salmeterol 100/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The x-axis shows the weeks, and the y-axis represents the percentage change in FEV1. A table below lists sample sizes per group at various time points.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

Line graph showing the percentage change in FEV1 over 12 hours on Day 1 baseline for four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. The graph illustrates comparative respiratory function changes post-dose.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

A line graph depicting the percentage change in FEV1 relative to Day 1 baseline over 12 hours. It compares four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The y-axis shows % change in FEV1, and the x-axis shows time in hours from baseline to 12 hours.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

A line graph depicting the percent change in FEV1 over 24 weeks for three groups: Fluticasone propionate/salmeterol DISKUS 250/50 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. Data points show FEV1 changes from baseline with the number of subjects (N) listed for each group at intervals.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

Line graph depicting the percent change in FEV1 over time for three groups: fluticasone propionate/salmeterol 250/50 mcg twice daily, fluticasone propionate 250 mcg twice daily, and placebo. The x-axis shows days and weeks up to 24 weeks; the y-axis shows percent change in FEV1. The combination therapy shows the greatest improvement compared to fluticasone alone and placebo.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

An illustration diagram of the Fluticasone Propionate and Salmeterol DISKUS inhaler device showing labeled parts: outer case, mouthpiece, lever, counter, and thumb grip. The label on the device indicates it contains 60 blisters of powder with 100 mcg fluticasone propionate and 50 mcg salmeterol per dose.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

Illustration showing a person holding a Fluticasone Propionate and Salmeterol DISKUS inhaler with an arrow indicating the direction to slide the inhaler mechanism, demonstrating how to prepare the device for use.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler with an arrow indicating the device should be slid open to prepare for inhalation.*

FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

An instructional illustration showing a woman holding a DISKUS inhaler device next to her mouth, demonstrating the proper inhalation technique for respiratory medication delivery. The image emphasizes correct positioning of the device for inhaling powder medication.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

An instructional illustration showing a woman using the Fluticasone Propionate and Salmeterol DISKUS inhaler. The woman is holding the inhaler close to her mouth preparing to inhale, demonstrating the proper use of the respiratory powder inhalation device.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

Illustration showing a person holding a Fluticasone Propionate and Salmeterol DISKUS inhaler with both hands and pushing the inhaler lever to the left, indicated by a white directional arrow, demonstrating the step to prepare the dose for inhalation.*

FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

An instructional grayscale illustration shows a woman performing a mouth rinse and spit technique using water from a faucet. This figure likely demonstrates a post-inhalation oral hygiene step relevant to respiratory inhalation medications.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS inhalation powder, 100 mcg/50 mcg strength, in a black plastic DISKUS device. The label indicates 60 blisters and shows the product name, strength, and a space for pouch opened and use by date. The design is compact with a mouthpiece and a dose counter showing the number 5.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.